Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



ECCO-ESMO: Erbitux combined with FOLFIRI or FOLFOX4 significantly extends overall survival in advanced bowel cancer

28 Sep 09

A meta-analysis of the CRYSTAL and OPUS studies involving 845 patients with metastatic colorectal cancer (mCRC) tumours displaying the wild-type KRAS gene, has revealed first-line treatment with Erbitux (cetuximab) and FOLFOX4 or FOLFIRI chemotherapy significantly extends overall survival.
Olwen Glynn Owen

‘No Frills Drugs’ push Pharmaceutical companies to look for a cure

25 Sep 09

With the pharmaceutical industry heading into the well documented “expiry cliff” competition is rife. Quicker more cost effective methods of manufacturing must be found for big pharma to remain competitive and a clearer means of communication such as that seen at the NG Pharma Summit is clearly vital.
NG Online News

What does the multi-channel enabled pharma’ company look like?

17 Sep 09

Hardly a day goes by without a new report, today AT Kearney, last week Roland Berger and before them IMS and PWC warning of a gloomy future for pharmaceutical companies and saying that they must change their ways.
Paul Dixey, Managing Partner, BlueLight Partners

Medical Animation, Innovation and Communication

16 Sep 09

Medical animation is increasinlgy being employed by pharmaceutical companies to explain the scientific rationale behind their products.
Faiz Kermani

What Employers Really Want

16 Sep 09

In the eyes of many graduates, the economic recession has brought a new-found negativity to the job market. Thankfully, the climate is probably less dire than the situation sometimes imagined.
Max Golby

Can Schering-Plough’s asenapine improve prospects for schizophrenia and bipolar patients

16 Sep 09

More than half of schizophrenia patients are expected to relapse within two years if untreated and 4 out of 5 within five years, according to experts. Antipsychotics can reduce the relapse rate so long as patients continue on treatment. However, adherence is notoriously poor. A new antippsychotic – asenapine – shows promise of being effective and better tolerated.
Olwen Glynn Owen

Swine Flu Update: 10/09/2009

14 Sep 09

Weekly Swine Flu Update for the Week Ending September 10th
Max Golby

Swine Flu Update: 04/09/2009

04 Sep 09

Weekly Swine Flu Update for the Week Ending September 4th.
Max Golby

The Future of e-Detailing: 2009 and Beyond

03 Sep 09

Max Golby, Freelance Journalist, takes a look at the history of the e-Detailing market, considers what the e-Detail of the future might look like and asks what marketing departments can learn from an academic analysis of the instrument.
Max Golby

Swine Flu Update: 28/08/2009

28 Aug 09

Weekly Swine Flu Update for the Week Ending August 27th.
Max Golby

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.